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Abstract
Background: In vitro studies confirmed cytoreductive anti-tumor activity of crizotinib in experimental models of
anaplastic large cell lymphoma in 2007. One case series and a few case reports describe the use of crizotinib in
relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Even though data are
limited regarding the dose of crizotinib in renal insufficiency, our case was successfully treated with a lower dose of
crizotinib.
Case presentation: We report the case of a 48-year-old white man who had progressive disease after three prior
cycles of cyclophosphamide, doxorubicin, vincristine and prednisone and three cycles of ifosfamide, carboplatin,
and etoposide, and was not a candidate for high-dose chemotherapy and transplant due to poor performance
status and renal insufficiency; he had a complete and durable response to single agent crizotinib. Crizotinib was
given at a reduced dose (250 mg once daily) due to his renal insufficiency. He has been in complete remission for
more than 2 years.
Conclusions: Our experience confirms the activity of crizotinib in this disease; it suggests that long-term treatment
with crizotinib is a reasonable option in patients who are not candidates for more aggressive therapy and indicates
that crizotinib can be used successfully at reduced doses in patients with pre-existing renal insufficiency. The role
and timing of crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma is unclear, but the
current literature that we review here provides promising results that may lead to studies of crizotinib earlier in the
course of disease.
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Background
Systemic anaplastic large cell lymphoma (ALCL) is a
rare subtype of peripheral T cell lymphoma representing
approximately 3 % of non-Hodgkin’s lymphoma (NHL),
often presenting with advanced disease, B symptoms and
extranodal disease [1]. Anaplastic lymphoma kinase-
positive (ALK+) ALCL is characterized by a specific
chromosomal translocation, t(2;5)(p23;35) which fuses
the ALK gene on chromosome 2 with the nucleophosmin
(NPM) gene on chromosome 5, resulting in a NPM-ALK
fusion protein, ALK overexpression and constitutive
tyrosine kinase activity [2]. Other partner genes for ALK
translocation events have been described, including
TPM3, TFG, MSN, CLTC, and ATIC. However, NPM-
ALK accounts for more than 75 % of the ALK+ ALCL
cases reported [3, 4]. ALK+ ALCL generally have a good
response to standard chemotherapy and relatively good
prognosis, with approximately 60 % of patients
remaining in remission 5 years after frontline therapy
[5]. However, the prognosis of patients with refractory
or relapsed disease is poor [6]. Furthermore, the small
cell variant of ALK+ ALCL has a worse prognosis [7].
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Approaches to treatment of relapsed or refractory dis-
ease have included high-dose chemotherapy and autolo-
gous stem cell transplant (auto-SCT), allogeneic stem
cell transplant (allo-SCT), and a number of second-line
chemotherapy agents including brentuximab vedotin [8].
Recently, several case reports and small series have
shown impressive responses of relapsed/refractory ALK+
ALCL to crizotinib, a specific inhibitor of the ALK kin-
ase. We now report further a case of a patient with re-
fractory ALK+ ALCL with a complete durable response
to single agent crizotinib. This patient has been in (CR)
for more than 2 years, on a reduced dose of crizotinib
due to pre-existing renal failure.
Case presentation
Our patient was a 48-year-old white man with past med-
ical history of diabetes mellitus type 2 who was diag-
nosed with stage IV ALK+ ALCL, small cell variant,
after presenting with B symptoms, right axillary and
supraclavicular lymphadenopathy and splenomegaly.
ALK positivity was confirmed using immunohistochem-
istry and fluorescent in situ hybridization employing an
ALK break-apart probe. He received three cycles of
cyclophosphamide, doxorubicin, vincristine, and pred-
nisolone (CHOP) but had progression of disease with a
necrotic spleen, continued B symptoms, and a malignant
left pleural effusion. He was subsequently treated with
splenectomy and drainage of the pleural effusion with a
PleurX catheter, and his chemotherapy was changed to
ifosfamide, carboplatin, and etoposide (ICE) in an at-
tempt to prepare for an auto-SCT. The pathology from
his spleen showed persistent viable lymphoma. He re-
ceived three cycles of ICE chemotherapy. He initially
partially responded to it, but the therapy was compli-
cated by episodes of encephalopathy due to ifosfamide
and the development of progressive renal insufficiency.
His baseline serum creatinine was 0.8 mg/dl, but it rose
to 1.8 mg/dl by the time of the third cycle of ICE and
subsequently peaked at a level of 5 to 6 mg/dl 2 months
later. A renal biopsy showed lymphocytic interstitial
nephritis.
Crizotinib, at a dose of 250 mg twice a day, was added
to the regimen immediately following the second cycle of
ICE, but it was discontinued after 7 days due to diarrhea.
Six weeks after receiving his third cycle of ICE, he again
developed fevers (temperatures >39 °C), axillary adenopa-
thy, and a decline in Eastern Cooperative Group (ECOG)
performance status from 1 to 3. Persistent disease was
demonstrated by 18F-fluorodeoxyglucose (FDG) avidity on
positron emission tomographic (PET) and computed
tomographic (CT) images of his retroperitoneal and right
axillary lymph nodes. We thought that he was no longer a
candidate for auto-SCT or allo-SCT due to a poor per-
formance status, resistant disease, and renal failure.
Crizotinib was restarted at a dose of 250 mg once a day
(Day 0). His fevers disappeared within 24 hours. Other B
symptoms and palpable axillary adenopathy resolved in a
week. PET and CT images performed at Day 76 showed
complete resolution of previously FDG-avid lesions (Fig. 1).
His CR has persisted for 29 months on continued therapy
with 250 mg of crizotinib orally once daily. Adverse effects
including transient thrombocytopenia and diarrhea have
been mild. His renal disease has stabilized with creatinine
levels between 4 mg/dl and 5 mg/dl without specific treat-
ment and without the need for dialysis.
Crizotinib is a well-tolerated small molecule inhibitor of
the ALK tyrosine kinase. It has significant activity in non-
small cell lung cancers (NSCLCs) bearing an activating
EML4-ALK translocation and is approved by the US Food
and Drug Administration (FDA) for this indication.
Crizotinib has been shown to have in vitro activity against
ALK-positive lymphomas [9]. Crizotinib induces apoptosis
due to down-regulation of pSTAT3 and BCL-2 family pro-
teins [10] and has excellent potential to treat patients with
refractory ALK-positive ALCL, such as our case.
Several case reports and small series have appeared on
the use of crizotinib in adult patients with relapsed/re-
fractory ALK+ ALCL which indicate that such lymph-
omas have a high chance of responding to crizotinib,
even when heavily pretreated, with approximately half
enjoying long-lasting responses; however, no pretreat-
ment parameter is able to predict a durable CR [11–14].
These cases are summarized in Table 1. A high percent-
age of patients, but not all, respond to treatment with
prompt resolution of B symptoms and rapid complete
Fig. 1 a 18F-fluorodeoxyglucose positron emission tomography/
computed tomography on Day 0 shows significant retroperitoneal
lymphadenopathy. b 18F-fluorodeoxyglucose positron emission
tomography/computed tomography on Day 76 shows complete
resolution of the retroperitoneal lymphadenopathy
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radiographic responses as shown by PET-CT. The crizo-
tinib dose generally used was 250 mg twice a day. The
treatment was well tolerated. In a number of the cases,
crizotinib was used as a bridge to allo-SCT, although in
one of those studies the patient relapsed in 4 weeks on
crizotinib before the allo-SCT could be done [12]. Other
patients have continued on treatment with single agent
crizotinib with durable response. In the largest of these
series, reported by Gambacorti Passerini et al., crizotinib
was given to nine patients with refractory/relapsed ALK
+ ALCL and all of them responded initially. Four of
these patients remained in CR on continuous crizotinib
therapy at 21 to 40 months follow-up. Two had under-
gone allo-SCT and remain in CR, of which one was still
on crizotinib. Two of the nine patients had subsequent
progression of the disease [11]. A prospective phase I
trial in pediatric patients with several malignancies was
performed by the Children’s Oncology Group. It showed
that of nine patients with ALK-mutated NHL, eight
responded and seven had CRs and five remained on cri-
zotinib in long-term remission [15].
Our patient did not tolerate crizotinib given at full
dose in combination with ICE chemotherapy. It is un-
clear if this was due to concomitant ICE chemotherapy
or due to decreased clearance of the drug due to his
renal insufficiency. Crizotinib was restarted at a reduced
dose of 250 mg daily as a single agent after recovery
from the last cycle of ICE chemotherapy. He has toler-
ated this without problems and without further kidney
injury or the need for dialysis. Renal pathology had
showed acute interstitial nephritis, which was thought to
be secondary to proton pump inhibitor (PPI) that was
initiated around that time and the PPI was stopped im-
mediately. At the time of initiation of reduced dose of
crizotinib, no literature was available on the interaction
of crizotinib with reduced renal function. In NSCLC
trials, crizotinib at 250 mg twice a day reaches steady
state in 15 days and then dose levels decrease non-
linearly. There were no differences in pharmacokinetics
(PK) levels for mild to moderate renal insufficiency. It
would be a good study question to look at the PK levels
for crizotinib in patients with renal impairment in condi-
tions other than NSCLC. Recent literature recommends
arbitrary dose adjustment (200 mg twice a day or 250
mg once daily) in the presence of renal insufficiency
[16], but the exact dosing in this situation still remains
unknown and further research is needed.
Conclusions
This experience suggests that single agent crizotinib is a
viable option for patients with relapsed/refractory ALK+
ALCL who are not candidates for high-dose chemother-
apy and auto-SCT or allo-SCT. Since crizotinib can yield
long-term remissions in patients with relapsed/refractory
ALK+ ALCL, it is unclear if all patients with relapsed/re-
fractory disease require high-dose chemotherapy and
allo-SCT even if they are candidates for it. In addition,
this experience demonstrated that crizotinib could be
successfully employed at reduced doses in patients with
renal insufficiency.
Table 1 Reported cases of the use of crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
Study Age Stage
(Ann Arbor)
ECOG Previous therapy lines Response, in months
Gambacorti Passerini et al. 2014 [11] 26 IIIB 2 CHOP, DHAP, HD-VP16 CR, >40
19 IVB 3 CHOP, DHAP, BEAM CR, 2
22 IIB 1 CHOP, VAD, H-CyVAD CR, >35
20 IIB 2 CHOP, DHAP, BEAM CR, 2
47 IIIB 2 IEV, CHOP, DHAP CR, >30
28 IIIBe 2 CHOP, DHAP, miniBEAM CR, 2
34 IVBe 2 CHOP, ESHAP CR, 3
38 IVB 4 CHOP, DHAP, VIM CR, 8
55 IIIB 1 CHOP CR, >21
Ordemann et al. 2013 [12] 29 na na CHOP-21, DHAP, Dexa-BEAM PR, 1
Cleary et al. 2014 [13] 34 na na CHOP, gemcitabine-based therapy,
pralatrexate, Mtx, brentuximab
CR, 30; allo-SCT at week 13
Conyers et al. 2014 [14] 22 IIIB na CHOP CR, >21; allo-SCT at 2 months
Current case 48 IV 3 CHOP, ICE CR, >29
allo-SCT allogeneic stem cell transplant, BEAM carmustine, etoposide, cytarabine, melphalan, CHOP cyclophosphamide, doxorubicin (adriamycin), vincristine,
prednisone, CR complete response, Dexa-BEAM dexamethasone, carmustine, etoposide, cytarabine, melphalan, DHAP dexamethasone, cisplatin, cytarabine, ECOG
Eastern Cooperative Group, ESHAP etoposide, methylprednisolone, cytarabine, cisplatin, H-CyVAD alternate regimens of 1) cyclophosphamide, vincristine,
doxorubicin (adriamycin), dexamethasone; 2) methotrexate and cytarabine; HD-VP16 high-dose etoposide, ICE ifosfamide, carboplatin, etoposide, IEV Ifosfamide,
epirubicin, etoposide, miniBEAM carmustine, etoposide, cytarabine, melphalan, Mtx methotrexate, na not available, PR partial response, VAD vincristine, doxorubicin,
high-dose dexamethasone, VIM ifosfamide, mitoxantrone, etoposide
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